Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2453255 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL2054368 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL20711832 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5742883 | 1.00 | MEN1 (0.43) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL29550748 | 0.96 | MEN1 (0.41) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5940491 | 0.96 | MEN1 (0.41) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL5940482 | 0.96 | MEN1 (0.41) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL29550782 | 0.96 | MEN1 (0.41) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL26547622 | 0.93 | MEN1 (0.42) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 | |
| SCHEMBL25706923 | 0.92 | MEN1 (0.38) | MEN1KMT2AALDH1A1HSD17B10L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025064683-A1 | SMALL MOLECULE PROTEIN SYNTHESIS MODULATORS | Interdict Bio, Inc. (US) | 2025-03-27 | — | — | WO | disclosed |
| WO-2025051148-A1 | NITROGEN-CONTAINING HETEROARYL COMPOUND, AND PREPARATION METHOD THEREFOR AND USE THEREOF | 北京鞍石生物科技股份有限公司 | 2025-03-13 | — | — | WO | disclosed |
| CN-119320383-A | Nitrogen-containing heteroaryl compound, and preparation method and application thereof | 北京鞍石生物科技股份有限公司 | 2025-01-17 | — | — | CN | disclosed |
| EP-1412328-B1 | DOLASTATIN 10 DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2006-10-04 | — | — | EP | disclosed |
| US-6878736-B1 | Histamine H3 receptor ligands | JAMES BLACK FOUNDATION LIMITED (GB) | 2005-04-12 | — | — | US | disclosed |
| US-6737409-B2 | FOR CANCER THERAPY | HOFFMANN-LA ROCHE INC. | 2004-05-18 | — | — | US | disclosed |
| EP-1412328-A1 | DOLASTATIN 10 DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2004-04-28 | — | — | EP | disclosed |
| EP-1056733-B1 | HISTAMINE H3 RECEPTOR LIGANDS | BLACK JAMES FOUNDATION (GB) | 2004-01-07 | — | — | EP | disclosed |
| US-20030055002-A1 | Dolastatin 10 derivatives | HOFFMANN-LA ROCHE INC. | 2003-03-20 | — | — | US | disclosed |
| WO-2003008378-A1 | DOLASTATIN 10 DERIVATIVES | F.HOFFMANN-LA ROCHE AG (CH) | 2003-01-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030055002-A1 | Dolastatin 10 derivatives | DAD1, DDOST, NPC1 | MEN1 1634/4885KMT2A 4793/4885ALDH1A1 2366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.